Performance of Mid-Treatment Breast Ultrasound and Axillary Ultrasound in Predicting Response to Neoadjuvant Chemotherapy by Breast Cancer Subtype

被引：23

作者：

Candelaria, Rosalind P. ^{[1
]}

Bassett, Roland L. ^{[2
]}

Symmans, William Fraser ^{[3
]}

Ramineni, Maheshwari ^{[3
]}

Moulder, Stacy L. ^{[4
]}

Kuerer, Henry M. ^{[5
]}

Thompson, Alastair M. ^{[5
]}

Yang, Wei Tse ^{[1
]}

机构：

[1] Univ Texas MD Anderson Canc Ctr, Dept Diagnost Radiol, Unit 1350, 1515 Holcombe Blvd, Houston, TX 77030 USA

[2] Univ Texas MD Anderson Canc Ctr, Dept Biostat, Unit 1411, Houston, TX 77030 USA

[3] Univ Texas MD Anderson Canc Ctr, Dept Pathol, Unit 1445, Houston, TX 77030 USA

[4] Univ Texas MD Anderson Canc Ctr, Dept Breast Med Oncol, Unit 1354, Houston, TX 77030 USA

[5] Univ Texas MD Anderson Canc Ctr, Dept Breast Surg Oncol, Unit 1434, Houston, TX 77030 USA

来源：

ONCOLOGIST | 2017年 / 22卷 / 04期

关键词：

Breast cancer; Ultrasound; Neoadjuvant therapy; CARCINOMA IN-SITU; RESIDUAL DISEASE; PATHOLOGICAL RESPONSE; SYSTEMIC TREATMENT; CLINICAL-TRIALS; TUMOR RESPONSE; MRI; ACCURACY; RECOMMENDATIONS; MAMMOGRAPHY;

D O I：

10.1634/theoncologist.2016-0307

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Background. The primary objective was to determine whether mid-treatment ultrasound measurements of index breast tumors and index axillary nodes of different cancer subtypes associate with residual cancer burden (RCB). Methods. Patients with invasive breast cancer who underwent neoadjuvant chemotherapy and had pre-treatment and mid-treatment breast and axillary ultrasound were included in this single-institution, retrospective cohort study. Linear regression analysis assessed associations between RCB with (a) change in index breast tumor size, (b) change in index node size, and (c) absolute number of abnormal nodes at mid-treatment. Multivariate linear regression was used to calculate best-fit models for RCB. Results. One hundred fifty-nine patients (68 triple negative breast cancer [TNBC], 45 hormone receptor [HR] + /human epidermal growth factor receptor 2 [HER2]-, and 46 HR-/HER2+) were included. Median age at diagnosis was 50 years, range 30-76. Median tumor size was 3.4 cm, range 0.9-10.4. Pathological complete response/RCB-I rates were 36.8% (25/68) for TNBC patients, 24.4% (11/45) for HR+/HER2- patients, and 71.7% (33/46) for HR-/HER2+ patients. Linear regression analyses demonstrated associations between percent change in tumor ultrasound measurements at mid-treatment with RCB index score in TNBC and HR+/HER2- (p < .05) but not in HR-/HER2+ (p > .05) tumors and an association between axillary ultrasound assessment of number of abnormal nodes at mid-treatment with RCB index score across all subtypes (p < .05). Conclusion. Performance characteristics of breast ultrasound associated with RCB vary by cancer subtype, whereas the performance characteristics of axillary ultrasound associated with RCB are consistent across cancer subtype. Breast and axillary ultrasound may be valuable in monitoring response to neoadjuvant therapy.

引用

页码：394 / 401

页数：8

共 38 条

[1]

[Anonymous], 2002, Model selection and multimodel inference: a practical informationtheoretic approach

[2]

Arimappamagan A, 2004, Indian J Cancer, V41, P13

[3] Sequential preoperative or postoperative docetaxel added to preoperative doxorubicin plus cyclophosphamide for operable breast cancer: National Surgical Adjuvant Breast and Bowel Project Protocol B-27 [J].

Bear, HD ;

Anderson, S ;

Smith, RE ;

Geyer, CE ;

Mamounas, EP ;

Fisher, B ;

Brown, AM ;

Robidoux, A ;

Margolese, R ;

Kahlenberg, MS ;

Paik, S ;

Soran, A ;

Wickerham, DL ;

Wolmark, N .

JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (13) :2019-2027

[4] Cortical morphologic features of axillary lymph nodes as a predictor of metastasis in breast cancer: In vitro sonographic study [J].

Bedi, Deepak G. ;

Krishnamurthy, Rajesh ;

Krishnamurthy, Savitri ;

Edeiken, Beth S. ;

Le-Petross, Huong ;

Fornage, Bruno D. ;

Bassett, Roland L., Jr. ;

Hunt, Kelly K. .

AMERICAN JOURNAL OF ROENTGENOLOGY, 2008, 191 (03) :646-652

[5] Recommendations for standardized pathological characterization of residual disease for neoadjuvant clinical trials of breast cancer by the BIG-NABCG collaboration [J].

Bossuyt, V. ;

Provenzano, E. ;

Symmans, W. F. ;

Boughey, J. C. ;

Coles, C. ;

Curigliano, G. ;

Dixon, J. M. ;

Esserman, L. J. ;

Fastner, G. ;

Kuehn, T. ;

Peintinger, F. ;

von Minckwitz, G. ;

White, J. ;

Yang, W. ;

Badve, S. ;

Denkert, C. ;

MacGrogan, G. ;

Penault-Llorca, F. ;

Viale, G. ;

Cameron, D. .

ANNALS OF ONCOLOGY, 2015, 26 (07) :1280-1291

[6] Axillary Ultrasound After Neoadjuvant Chemotherapy and Its Impact on Sentinel Lymph Node Surgery: Results From the American College of Surgeons Oncology Group Z1071 Trial (Alliance) [J].

Boughey, Judy C. ;

Ballman, Karla V. ;

Hunt, Kelly K. ;

McCall, Linda M. ;

Mittendorf, Elizabeth A. ;

Ahrendt, Gretchen M. ;

Wilke, Lee G. ;

Le-Petross, Huong T. .

JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (30) :3386-+

[7] MRI evaluation of pathologically complete response and residual tumors in breast cancer after neoadjuvant chemotherapy [J].

Chen, Jeon Hor ;

Feig, Lyon ;

Agrawal, Garima ;

Yu, Hon ;

Carpenter, Philip M. ;

Mehta, Rita S. ;

Nalcioglu, Orhan ;

Su, Min Ying .

CANCER, 2008, 112 (01) :17-26

[8] Breast Cancer: Evaluation of Response to Neoadjuvant Chemotherapy with 3.0-T MR Imaging [J].

Chen, Jeon-Hor ;

Bahri, Shadfar ;

Mehta, Rita S. ;

Kuzucan, Aida ;

Yu, Hon J. ;

Carpenter, Philip M. ;

Feig, Stephen A. ;

Lin, Muqing ;

Hsiang, David J. B. ;

Lane, Karen T. ;

Butler, John A. ;

Nalcioglu, Orhan ;

Su, Min-Ying .

RADIOLOGY, 2011, 261 (03) :735-743

[9] Extent of ductal carcinoma in situ according to breast cancer subtypes: a population-based cohort study [J].

Doebar, Shusma C. ;

van den Broek, Esther C. ;

Koppert, Linetta B. ;

Jager, Agnes ;

Baaijens, Margreet. H. A. ;

Obdeijn, Inge-Marie A. M. ;

van Deurzen, Carolien H. M. .

BREAST CANCER RESEARCH AND TREATMENT, 2016, 158 (01) :179-187

[10] New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1) [J].

Eisenhauer, E. A. ;

Therasse, P. ;

Bogaerts, J. ;

Schwartz, L. H. ;

Sargent, D. ;

Ford, R. ;

Dancey, J. ;

Arbuck, S. ;

Gwyther, S. ;

Mooney, M. ;

Rubinstein, L. ;

Shankar, L. ;

Dodd, L. ;

Kaplan, R. ;

Lacombe, D. ;

Verweij, J. .

EUROPEAN JOURNAL OF CANCER, 2009, 45 (02) :228-247

← 1 2 3 4 →